source
- Arvinas and Pfizer license newly approved PROTAC breast cancer drug Veppanu to Rigel PharmaceuticalsArvinas and Pfizer have signed a licensing agreement that transfers ownership of their newly approved breast cancer drug, Veppanu, to San Francisco‑based Rigel Pharmaceuticals. The deal gives Arvi…
- Immunotherapy trials like PODIUM-303 are reshaping treatment for squamous cell anal cancer, says Dr ParikhDr Aparna R. Parikh, an oncologist at Massachusetts General Hospital and Harvard professor, highlighted the growing feasibility of immunotherapy studies in squamous cell anal carcinoma (SCAC). She…